Recent studies hypothesized that vitamin D supplementation and subsequent higher 25(OH)D serum levels could protect against respiratory infections in children. This cross-sectional study, conducted from May 2022 to December 2023 in Timisoara, Romania, aimed to evaluate the potential influence of vitamin D supplementation on the incidence of respiratory infections among preschool-age children. This study examined 215 children over 18 months who were split into a group of patients with recurrent respiratory infections (n = 141) and another group of patients with only one respiratory tract infection in the past 12 months (n = 74). Patients were evaluated based on their serum vitamin D levels 25(OH)D, demographic characteristics, and health outcomes. The study identified that preschool-age children with recurrent infections had significantly lower mean vitamin D concentrations (24.5 ng/mL) compared to the control group (29.7 ng/mL, p < 0.001). Additionally, a higher proportion of vitamin D deficiency was observed among children with recurrent infections in the past 12 months. Notably, vitamin D supplementation above 600 IU/week significantly reduced the likelihood of respiratory infections, evidenced by an odds ratio of 0.523 (p < 0.001), indicating that preschool-age children receiving a dose of vitamin D higher than 600 IU/week were about half as likely to experience respiratory infections compared to those who did not. Furthermore, no significant associations were found between sun exposure, daily sunscreen use, and the incidence of respiratory infections. Conclusively, this study underscores the potential role of vitamin D in helping the immune system against respiratory infections in preschool-age children. The observed protective effect of vitamin D supplementation suggests a potential public health strategy to mitigate the incidence of respiratory infections in preschool children on top of the already known benefits.

The long-term sequelae of SARS-CoV-2 infection are still under research, since extensive studies showed plenty of systemic effects of the viral infection, extending even after the acute phase of the infection. This study evaluated kidney function tests six months after SARS-CoV-2 infection in patients clinically diagnosed with Post-COVID Syndrome, hypothesizing persistent renal dysfunction evidenced by altered kidney function tests compared to baseline levels. Continuous eGFR decrease <30 at six months post-infection was considered the main study outcome. Conducted at the “Victor Babes” Hospital, this retrospective observational study involved adults with laboratory-confirmed SARS-CoV-2 infection and clinically-diagnosed Post-COVID Syndrome, excluding those with prior chronic kidney disease or significant renal impairment. Kidney function tests, including serum creatinine, blood urea nitrogen (BUN), estimated glomerular filtration rate (eGFR), alongside markers of kidney damage such as proteinuria and hematuria, were analyzed. Among 206 participants, significant differences were observed between the control (n = 114) and the Post-COVID group (n = 92). The Post-COVID group exhibited higher serum creatinine (109.7 μmol/L vs. 84.5 μmol/L, p < 0.001), lower eGFR (65.3mL/min/1.73 m² vs. 91.2 mL/min/1.73 m², p < 0.001), and elevated BUN levels (23.7 mg/dL vs. 15.2 mg/dL, p < 0.001) compared to the control group. Regression analysis highlighted significant predictors of continuous eGFR decrease <30 at six months post-infection. The development of acute kidney injury (AKI) during the initial COVID-19 illness emerged as a strong predictor of reduced eGFR (β = 3.47, p < 0.001). Additional factors, including a creatinine increase (23 μmol/L above the normal range) and an elevated Albumin to Creatinine Ratio (ACR) (>11 mg/g above the normal range), were significantly associated with eGFR reduction. Patients with Post-COVID Syndrome demonstrate significant renal impairment six months post-SARS-CoV-2 infection. The study’s findings stress the need for ongoing monitoring and intervention strategies for renal health in affected individuals, underscoring the persistent impact of COVID-19 on renal function.

Background and Objectives: Recent studies suggest that vitamin D supplementation and higher serum 25-hydroxyvitamin D (25-OHD) concentrations may reduce the incidence of respiratory infections in children and adolescents. This cross-sectional study aimed to evaluate the association between different concentrations of vitamin D supplementation, serum 25-OHD concentrations, and the frequency of respiratory infections among individuals aged 1 to 18 years, for a duration of 2 years. Methods: Concerning sun exposure in relation to vitamin D, the study took place in Romania, at approximately 45-degree northern latitude. A total of 194 patients were divided into groups based on weekly vitamin D supplementation (800 IU), serum 25-OHD concentrations (30 ng/mL), and age (800 IU/week had a significantly lower incidence of infections (16.7%) compared to those receiving <400 IU/week (60.0%, p < 0.001). Similarly, participants with serum 25-OHD concentrations >30 ng/mL had an infection rate of 16.7%, compared to 61.4% in those with concentrations <20 ng/mL (p < 0.001). Age-specific analyses revealed that the protective effect of vitamin D was most pronounced in children under 6 years old. Logistic regression showed that higher vitamin D supplementation and serum 25-OHD concentrations were independently associated with reduced odds of respiratory infections (OR = 0.25 and OR = 0.22, respectively, p < 0.001). Conclusions: These findings support the potential role of vitamin D supplementation in preventing respiratory infections in the pediatric population.

Background & Objectives: Quantitative ultrasound (QUS) radiomics extracts microstructure-sensitive spectral features from radiofrequency data and may provide contrast-free, early indicators of neoadjuvant chemotherapy (NAC) response in breast cancer. This review synthesized open access human studies evaluating QUS radiomics for a priori prediction and early on-treatment monitoring. Methods: Following PRISMA-2020, we included English, free full-text clinical studies of biopsy-proven breast cancer receiving NAC that reported QUS spectral parameters (mid-band fit, spectral slope/intercept) ± textures/derivatives and machine learning models against clinical/pathologic response. Data on design, RF acquisition/normalization, features, validation, and performance (area under the curve (AUC), accuracy, sensitivity/specificity, balanced accuracy) were extracted. Results: Twelve cohorts were included. A priori baseline models achieved accuracies of 76–88% with AUCs 0.68–0.90; examples include 87% accuracy in a multi-institutional study, 82% accuracy/AUC 0.86 using texture-derivatives, 86% balanced accuracy with transfer learning, 88% accuracy/AUC 0.86 with deep learning, and AUC 0.90 in a hybrid QUS and molecular-subtype model. Early monitoring improved discrimination: week-1 results ranged from AUC 0.81 to 1.00 and accuracy 70 to 100%, noting that the upper bound was reported in a small cohort using combined QUS and diffuse optical spectroscopy features, while week 4 typically peaked (AUC 0.87–0.91; accuracy 80–86% in observational cohorts), and one series reported week-8 accuracy of 93%. Across reporting cohorts, mean AUC increased with a 0.05 absolute gain. A randomized feasibility study reported prospective week-4 model accuracy of 98% and demonstrated decision impact. Conclusions: QUS radiomics provides informative a priori prediction and strengthens by weeks 1–4 of NAC, supporting adaptive treatment windows without contrast or radiation. Standardized radiofrequency (RF) access, normalization, region of interest (ROI)/margin definitions, and external validation are priorities for clinical translation.

Background and Objectives: The worldwide shift toward psychiatric deinstitutionalization has aimed to enhance patient autonomy, social integration, and overall quality of life. However, limited studies have examined how concurrent substance use—particularly alcohol, marijuana, and inhalable drugs—affects clinical outcomes in these populations. This study aimed to evaluate psychiatric patients with varying degrees of institutionalization and investigate whether substance use complicates or exacerbates treatment outcomes. We hypothesized that individuals using substances would demonstrate worse psychosocial functioning, higher healthcare costs, and increased readmission rates. Methods: We performed a cross-sectional study of 95 participants recruited from long-term care facilities. Participants completed the SF-36 survey validated in Romanian. Financial data were collected to gauge direct and indirect healthcare expenditures. Results: Results indicated that 34.7% of participants reported alcohol use, 12.6% used marijuana, and 9.5% used inhalable substances. Substance-using patients experienced higher mean hospitalization costs of approximately USD 3251.8, compared to non-users (USD 2743.6, p = 0.032). Quality-of-life scores were significantly lower among substance users (mean SF-36 score 58.4 vs. 66.7, p = 0.027). Rates of relapse and readmission were also notably higher in the substance-using cohort (42.1%) relative to non-users (29.8%, p = 0.041). Conclusions: To our knowledge, this is the first Romanian study—and one of only a handful in Europe—to quantify how specific substance-use profiles simultaneously alter quality of life and direct healthcare costs in a deinstitutionalized psychiatric population. Our findings highlight the need for integrated interventions targeting both mental health and substance abuse.

Background and Objectives: Romania’s transition from long-stay psychiatric care to more balanced community-oriented care remains incomplete, and comparative patient-level data are limited. The primary objective was to compare mental health-related quality of life, autonomy, perceived coercion, and direct mental health costs across hospital, residential, and community care settings. Secondary objectives were (i) to compare hospital care with deinstitutionalized care taken together (residential + community), and (ii) to examine whether autonomy and perceived coercion were associated with mental health-related quality of life. Methods: In this cross-sectional study, 128 adults with severe mental illness (42 hospital, 43 residential, 43 community) completed the Romanian SF-36 v2.0 and two brief study-specific rating scales for autonomy and perceived coercion. Service-use and cost data for the previous 12 months were extracted from records. Results: Community participants had higher SF-36 mental scores than hospital patients (63.3 ± 7.6 vs. 52.8 ± 9.1) and higher autonomy (72.1 ± 10.0 vs. 53.0 ± 8.6), with lower perceived coercion (4.2 ± 1.3 vs. 6.4 ± 1.5; all p < 0.001). Mean combined direct costs in residential and community settings were approximately USD 1000 lower than in hospital care (USD 2671.6 vs. 3666.2; p < 0.001). When residential and community participants were analyzed together as a deinstitutionalized group, they also had higher SF-36 mental scores (59.7 ± 8.9 vs. 52.8 ± 9.1; p < 0.001). In multivariable models (R² = 0.316), each 10-point higher autonomy score was associated with a 2.8-point higher SF-36 mental score, whereas each 1-point higher coercion score was associated with a 1.3-point lower score. Exploratory mediation analysis suggested that autonomy statistically attenuated the association between deinstitutionalized care and mental quality of life. Conclusions: In this sample, residential and community arrangements outside hospital wards were associated with better mental health-related quality of life, higher autonomy, lower perceived coercion, and lower direct costs than long-stay hospital care. These findings support the study objective of comparing Romanian care settings and suggest that autonomy is an important correlate to target in future service reconfiguration and longitudinal research.